Keywords: kv, gynazole-1, targets, 175m, market, pharmaceutical, been
KV's Gynazole-1 targets $175M US market
Article | 15 June 2000
KV Pharmaceutical has been granted US approval for Gynazole-1(butoconazole nitrate 2% vaginal cream), a once-dose treatment for vaginal yeast infections. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
